POLYPEPTIDE GROUP AG/  CH1110760852  /

Nasdaq Other OTC
-  - Chg. - Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
-USD - 995
Turnover: -
-Bid Size: - -Ask Size: - 1.16 bill.USD - -

Business description

PolyPeptide Group is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world.
 

Management board & Supervisory board

CEO
Juan José Gonzalez
Management board
Marc Augustin, Christina Del Vecchio, Jens Fricke
Supervisory board
Peter Wilden, Patrick Aebischer, Beat In-Albon, Jane Salik, Erik Schropp, Philippe A. Weber
 

Company data

Name: POLYPEPTIDE N
Address: Neuhofstrasse 24,Baar
Phone: +41 435 020 580
Fax: -
E-mail: -
Internet: https://www.polypeptide.com/
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12-31
Free Float: 40.37%
IPO date: 2021-04-29

Investor relations

Name: Michael Stäheli
IR phone: +41 435 020 580
IR Fax: -
IR e-mail: investorrelations@po...ide.com investorrelations@polypeptide.com

Company calendar

CW 11 | 2025-03-11 4th Quarter/Annual Report
CW 15 | 2025-04-09 General Shareholder Meeting
CW 33 | 2025-08-12 Interim Report 2nd Quarter/6 Months
CW 11 | 2026-03-12 4th Quarter/Annual Report
CW 15 | 2026-04-08 General Shareholder Meeting
 

Main Shareholders

Cryosphere Foundation
 
56.10%
Others
 
27.28%
Premier Fund Managers Limited
 
5.17%
Premier Portfolio Managers Limited
 
4.93%
Rudolf Maag
 
3.32%
PRIMECAP Management Company
 
3.20%